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Juan J. Toro,1,2 David J. Haile,1 Ju-Hsien Chao,1 Deanna Schneider,1 Pamela S. Jewell,1
Shuko Lee,1 Cesar O. Freytes1,2The nutritional assessment of patients prior to autologous peripheral blood stem cell transplantation
(APBSCT) is labor intensive. A simple method of nutritional assessment prior to APSCTwould be extremely
helpful, especially if this method could identify patients at high risk of transplant-related complications. The
Department of Veterans Affairs (VA) developed a Nutritional Status Classification Scheme (NSCS) to identify
nutritionally compromised inpatients rapidly and reliably. The objective of this study was to determine if the
use of the VA-NSCS could be utilized as a tool for the evaluation of patients prior to APBSCTand to deter-
mine if this tool could be used to identify patients at high risk of transplant-related complications. The nu-
tritional status of 128 patients who underwent APBSCT was assessed by a registered dietician, utilizing
the VA-NSCS, upon admission to the hospital and prior to conditioning regimen. Patients with moderately
compromised nutritional status pretransplantation experienced a higher incidence of infections, longer du-
ration of diarrhea, and longer length of hospital stay when compared to patients with normal or mildly com-
promised nutritional status. Our study demonstrates that the VA-NSCS, a simple and inexpensive tool to
assess nutritional status, was useful in determining the pretransplant nutritional status of patients with lym-
phogenous malignancies who underwent APBSCT. In addition, this method was able to identify patients at
a higher risk of posttransplant complications. Future studies should be undertaken to determine the optimal
method for the nutritional assessment of autologous stem cell transplant candidates.
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Transplant-related complicationsINTRODUCTION
The nutritional status of patients prior to autolo-
gous peripheral blood stem cell transplantation
(APBSCT) is an important determinant of posttrans-
plant complications. Many nutritional status assess-1South Texas Veterans Health Care System, Audie L.
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6/j.bbmt.2009.05.004ment tools require tests that are not obtained
routinely or require anthropomorphic measurements,
which make the assessment of nutritional status labor
intensive [1-3]. A simplemethod of pretransplant nutri-
tional assessment with the capacity to identify patients
at high risk of transplant-related complications would
be extremely helpful, especially if this method is simple,
inexpensive, and does not require specialized tests.
The Department of Veterans Affairs (VA) devel-
oped a Nutritional Status Classification Scheme
(NSCS) to identify nutritionally compromised inpa-
tients rapidly and reliably. The VA-NSCS takes into
account a combination of body weight, routine labora-
tory tests, and clinical and dietary history. The
VA-NSCS is routinely utilized for the nutritional eval-
uation of inpatients in the VA system. The VA system
population is comprised mostly of males (90%), with
an average age of 59 years (range: 29-79 years) [4].
Biol Blood Marrow Transplant 15:1060-1065, 2009 1061Assessment of Nutritional Status Prior to Autologous TransplanationThe objective of this study was to determine if the
use of the VA-NSCS could be utilized as a tool for the
evaluation of patients prior to APBSCT and to deter-
mine if this tool could be used to identify patients at
high risk of transplant-related complications.PATIENTS AND METHODS
A 2-hospital prospective study was conducted at
Audie L. Murphy Memorial Veterans Hospital and
University Hospital in San Antonio, Texas. The
University of Texas Health Science Center at San
Antonio institutional review board approved the
study protocol, and all patients gave written in-
formed consent before any study-related procedures
was performed.
Study Subjects
One hundred thirty-five consecutive patients, age
18 years or older, who underwent APBSCT for multi-
ple myeloma (MM) or lymphoma at both hospitals be-
tween June 22, 2005, and July 14, 2008, were invited to
participate in the study. Six patients declined to partic-
ipate in the study, and 1 patient was considered not
evaluable because of his death 5 days after transplanta-
tion. The final study cohort consisted of 128 patients.
Patients with MM received melphalan (Mel) 100 mg/
m2 daily for 2 days (total 200 mg/m2) as the condition-
ing regimen. Patients with lymphoma received 1 of 2
conditioning regimens: cyclophosphamide (Cy)
1800 mg/m2/day for 4 days, etoposide 400 mg/m2
every 12 hours for 3 days, and carmustine 450 mg/
m2/day for 1 day (CBV); or carmustine 300 mg/m2/
daily for 1 day, etoposide 100 mg/m2 every 12 hours
for 4 days, cytarabine 100 mg/m2 every 12 hours for
4 days, and Mel 140 mg/m2/daily for 1 day (BEAM).
Nutritional Assessment
A registered dietician at each institution assessed
the nutritional status of the patients utilizing the VA-
NSCS upon the patient’s admission to the hospital
and prior to the administration of the conditioning
regimen.
The NSCS is a validated instrument developed by
the VA that stratifies patients in 4 nutritional levels or
status levels: normal, mildly compromised, moderately
compromised, and severely compromised based on 7
individual clinical indicators (Table 1). These 7 clini-
cal indicators include nutritional history, uninten-
tional weight loss, weight as body mass index, diet,
diagnosis, serum albumin, and total lymphocyte count.
Ratings from 1 to 4 are assigned to each of the indica-
tors, and the overall nutritional status is determined by
a predefined algorithm in which the 3 indicators with
the highest values are added and the total defines the
overall nutritional status. As defined in the VA-NSCS algorithm, when data was not available for
a clinical indicator, it was not utilized and was not con-
sidered in the overall nutritional status determination.
The VA-NSCS was modified in our study to exclude
the total lymphocyte count because patients with lym-
phogenous malignancies might have received chemo-
therapy shortly before admission for transplantation,
and abnormalities of the lymphocyte count might
not reflect the patient’s nutritional status, but rather
the effect of recently administered chemotherapy. A
minimum of 4 of any of the 7 clinical indicators men-
tioned above were necessary to determine the overall
nutritional status [5].
Patient-, Disease-, and Transplant-Related
Characteristics
This was an observational study; the data was
collected by personnel not directly involved in the
clinical care of the study subjects. Patient- and dis-
ease-related characteristics including age, sex, ethnic-
ity, performance status as defined by the Karnofsky
score, primary diagnosis, and type of conditioning
regimen were obtained before initiation of chemo-
therapy. Posttransplant variables related to the clini-
cal course and complications obtained included the
presence and duration of fever, the presence and du-
ration of diarrhea, the presence of infection, days to
neutrophil engraftment (first day of 2 consecutive
days of absolute neutrophil count [ANC] $500/mL
after reaching the ANC nadir), days to platelet en-
graftment (first day of 2 consecutive days of platelet
count $20,000/mL without transfusion support after
reaching the platelet nadir), days with severe neutro-
penia (defined as ANC# 500/mL), and length of hos-
pital stay (defined as the time from the first day of
the conditioning regimen until hospital discharge).
Patients were followed until resolution of all post-
tranplant-related toxicities.
Statistical Analysis
Statistical analyses were performed using SAS
version 9.3 (SAS Institute Inc., Cary, SC). Patient
characteristics, including demographics and clinical
information, were expressed as mean and standard
deviation,median and interquartile range, and frequency
and percentage. Patient characteristics were compared
among the 3 nutritional status groups by chi-square
test for discrete variables, by analysis of variance for
normally distributed continuous variables, and by
Kruskal-Wallis test for nonnormally distributed con-
tinuous variables. The adjustment for multiple com-
parisons of variables that yield a significant result
such as hospital length of stay and days with diarrhea
was performed by Tukey-Kramer method. Karnofsky
score was examined with post hoc test, Bonferroni cor-
rection, to adjust P-value for multiple comparisons.
Table 1. Modified Veterans Affairs Nutritional Status Classification Scheme
Indicator Normal nutritional status 1
Mildly compromised
nutritional status 2
Moderately compromised
nutritional status 3
Severely compromised
nutritional status 4
Nutritional history Good appetite, no eating/
digestion problems,
independent activities of
daily living
Fair appetite, chewing
problems, constipation,
nausea, requires feeding
assistance, restricted
ambulation, limited
activities of daily living
Poor appetite, vomiting,
diarrhea, swallowing
problems
No appetite
Unintentional weight loss as
a % of usual body weight
Stable weight (no weight
loss)
<10% in 6 months 10%–15% in 6 months or
<7.5% in 3 months or
<5% in 1 month or <2% in
1 week
>15% in 6 months or$7.5%
in 3 months or $5% in 1
month or$2% in 1 week
Weight as a % ideal body
weight (IBW)
100-90% IBWor <119%
IBW
89–81% IBWor
120%–129% IBW
80–75% IBWor
130%–149% IBW
#74% IBWor $150% IBW
Diet Mechanical, regular ADA/weight reduction, any
consistency other than
mechanical, drug-
nutrient interaction,
lactose free, low fat/low
cholesterol, sodium
restricted, dysphagia
Fluid restriction (<1000 cc),
mineral restricted other
than sodium, protein
restricted, tube feeding
(stable)
Clear liquids >3 days,
nothing by mouth >3
days, partial parenteral
nutrition, total parenteral
nutrition, tube feeding
(unstable)
Diagnosis All surgeries not
mentioned, HIV positive,
hypertension,
psychological disorders,
urology disorders
Alzheimer disease, angina,
cancer except gastro-
intestinal (GI) tract, head,
and neck cardiac disease,
cellulitis, congestive
heart failure (CHF)
(stable), chronic
obstructive pulmonary
disease (COPD), (stable),
cerebrovascular accident,
dementia, diabetes
(controlled), endocrine
other, than diabetes,
fracture, GI disease (all
other) neurological
disorders, nutritional
anemia, pneumonia,
psychological eating
disorder, peripheral
vascular disease,
radiation therapy (except
GI tract, head and neck),
renal disease, substance
abuse, abdominal
surgery, total hip
replacement,
tuberculosis
AIDS, cancer involving GI
tract or head and neck,
cardiomyopathy,
chemotherapy, CHF,
(acute), chronic renal
failure, COPD (unstable),
Crohn’s disease, diabetes
(uncontrolled), diabetes
(newly diagnosed),
dysphagia enteritis,
esophageal stricture,
fracture (traumatic), GI
disease with
malabsorption or
maldigestion, GI bleeding,
head trauma, infection
with fever, liver disease,
neurological disorders,
coma, pulmonary
disease, oxygen
dependent, radiation
therapy for GI tract, head
and neck spinal cord
injury (new), ulcerative
colitis
Acute renal failure, cardiac
cachexia, GI obstruction,
hepatic coma, hepatic
encephalopathy, ileus,
malnutrition, peritonitis,
pulmonary failure
ventilator dependent,
sepsis
Serum albumin (g/dL) $22 Standard
deviations (SD)
22.3 SD #23.3 SD 23.5 SD #24.6 SD #24.9 SD
Adapted from the Department of Veterans Affairs Nutritional Status Classification Scheme Handbook 1109.01 dated August 14, 2006.
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logistic analysis. A trend analysis was also performed to
find the association between the number of patients
that developed infection with nutritional status by
Mantel-Haenszel chi-square. Finally, we performed
multiple regression analysis with stepwise procedure
to predict the length (days) of hospital stay and dura-
tion (days) of diarrhea as dependent variables, and as
independent variables we used nutritional status, infec-
tion, and karnofsky score as ordinal number. Indepen-
dent variables were selected by value of P\ .2 from
previous univariate analyses. Independent variables
were kept in the final model if the value was P\ .1.
A value of P\ .05 was considered to be significant.RESULTS
Determination of Pretransplant
Nutritional Status
One hundred thirty-five consecutive patients with
lymphogenous malignancies underwent APBSCT
during the 3-year recruitment period. Of these, 128
(95%) patients agreed to participate in the study. Nu-
tritional assessments were completed successfully in
a single visit for all 128 patients utilizing the clinical
and basic laboratory information obtained upon ad-
mission to the hospital. On average, a registered dieti-
tian completed the nutritional assessment in
\30 minutes and the evaluation form in\5 minutes.
Table 3. Distribution of Patient’s Overall Nutritional Status
across Clinical Indicators
Indicator Normal
Mildly
compromised
Moderately
compromised
Severely
compromised
Nutritional
history
88 34 6 0
Unintentional
weight loss
85 14 10 5
Weight as a % of
ideal body weight
44 33 31 20
Diet 87 36 5 0
Diagnosis 0 118 9 1
Albumin 91 26 6 5
Overall score 26 91 11 0
Table 4. Patient Characteristics Stratified by Nutritional
Status
Pretransplant patient Mildly Moderately
Biol Blood Marrow Transplant 15:1060-1065, 2009 1063Assessment of Nutritional Status Prior to Autologous TransplanationTwenty-six (20%) of our patients had a normal nutri-
tional status as defined by the VA-NSCS, 91(71%) had
mildly compromised nutritional status and 11 (9%)
had moderately compromised nutritional status. No
patient met criteria for severely compromised nutri-
tional status.
Pretransplant Patient Characteristics
Demographic and baseline clinical characteristics
of the 128 evaluable subjects are shown in Table 2.
The median age of study subjects was 58 years (range:
19-74 years). Of the 128 patients, 119 (93%) were
males and 66 (52%) were Caucasian. Eighty-eight
(69%) patients had multiple myeloma (MM) as the un-
derlying diagnosis and received single agent Mel as
conditioning regimen. Twenty-nine (23%) patients
had non-Hodgkin lymphoma (NHL); of these, 8 pa-
tients received BEAM and 21 patients received CBV
as conditioning regimen. Only 11 (9%) patients had
a diagnosis of Hodgkin lymphoma (HL) and all re-
ceived CBV as conditioning regimen. The distribution
of patient’s nutritional status across clinical indicators
is illustrated on Table 3. None of the individual clini-
cal indicators consistently predicted for outcome (data
not shown).
No statistically significant differences between the
3 nutritional status groups were observed with respect
to age, sex, ethnicity, or diagnosis before transplanta-
tion (Table 4). A larger proportion of patients with
lymphoma who had moderately compromised nutri-
tional status received BEAM as conditioning regimen
instead of CBV (c25 10, P5 .041). This corresponds
to the fact that in our program, the BEAM regimen is
reserved for patients with lower performance status or
multiple comorbidities. In fact, the median KarnofskyTable 2. Pretransplant Characteristics of Study Population
(n5 128)
Age, years
Mean* 56.51 ± 10.60
Median (range) 58 (19-74)
Sex, n (%)
Male 119 (93)
Female 9 (7)
Ethnicity, n (%)
White 66 (52)
African American 24 (19)
Hispanic 34 (27)
Other 4 (3)
Primary diagnosis, n (%)
Multiple Myeloma 88 (69)
Non-Hodgkin Lymphoma 29 (23)
Hodgkin Lymphoma 11 (9)
Conditioning regimens, n (%)
Melphalan 88 (69)
BEAM 8 (6)
CBV 32 (25)
Median Karnofsky score (range) 90 (70-100)
BEAM indicates Carmustine, Cytarabine, Etoposide, and Melphalan;
CBV, Cyclophosphamide, Etoposide, and Carmustine.
*Presented as mean 6 standard deviations.performance status score before the initiation of the
conditioning regimen was significantly higher in pa-
tients with normal and mildly compromised nutri-
tional status compared with those with moderately
compromised nutritional status (c25 14.72, P5 .001)
(Table 4).Posttransplant-Related Toxicities
The posttransplant-related toxicities, as well as
engraftment and length of hospital stay of the study co-
hort are illustrated on Table 5. As expected, two-thirds
of the patients experienced fever and, in 40% of them,
infection was documented. Diarrhea was the most
common toxicity observed in our patient population.
Our median length of hospital stay was 18 days,characteristics Normal compromised compromised P-value
Median age, years
(range)
58 (19-74) 58 (23-74) 60 (46-73) .289*
Sex, n (%)
Male 25 (96%) 85 (93%) 9 (82%)
Female 1 (4%) 6 (7%) 2 (18%) .283†
Ethnicity, n (%)
Caucasian 13 (50%) 46 (51%) 7 (64%)
African American 6 (23%) 17 (19%) 7 (64%)
Hispanic 6 (23%) 25 (27%) 3 (27%)
Other 1 (4%) 3 (3%) 0 (0%) .946†
Primary diagnosis, n (%)
Multiple myeloma 16 (61%) 64 (70%) 8 (73%)
Non-Hodgkin
lymphoma
8 (31%) 18 (20%) 3 (27%)
Hodgkin lymphoma 2 (8%) 9 (10%) 0 (0%) .628†
Conditioning regimen, n (%)
Melphalan 16 (61%) 64 (70%) 8 (73%)
CBV 6 (23%) 25 (27%) 1 (9%)
BEAM 4 (15%) 2 (2%) 2 (18%) .041†
Median Karnofsky
score (range)
90 (80-100) 90 (70-100) 80 (80-90) .001‡
BEAM indicates carmustine, cytarabine, etoposide and melphalan; CBV,
cyclophosphamide, etoposide and carmustine.
*Analysis of variance (ANOVA).
†Chi-square.
‡Kruskal-Wallis test.
Table 5. Treatment-Related Toxicities Stratified by Nutritional Status
Study population Normal Mildly compromised Moderately compromised
Posttransplant-related variables n5 128 n5 26 n5 91 n5 11 P-value
Fever, n (%)
Yes 86 (67) 16 (62%) 63 (69%) 7 (64%)
No 42 (33) 10 (38%) 28 (31%) 4 (36%) .736*
Diarrhea, n (%)
Yes 110 (86) 23 (88%) 77 (85%) 10 (91%)
No 18 (14) 3 (12%) 14 (15%) 1 (9%) .781*
Infection, n (%)
Yes 51 (40) 5 (19%) 38 (42%) 8 (73%)
No 77 (60) 21 (81%) 53 (58%) 3 (27%) .008*
Days with fever† 2.54 ± 3.56 2.19 ± 2.37 2.70 ± 3.95 2.09 ± 2.47 .745‡
Days with diarrhea† 7.02 ± 5.45 6.54 ± 3.99 6.61 ± 5.07 12.00 ± 9.20 .010‡
Days to neutrophil engraftment† 10.87 ± 1.43 11.00 ± 1.06 10.87 ± 1.57 10.60 ± 0.84 .388‡
Days to platelet engraftment† 13.34 ± 4.37 13.85 ± 4.50 13.29 ± 4.55 12.40 ± 1.71 .722‡
Days with severe neutropenia† 7.50 ± 2.40 8.73 ± 2.44 8.52 ± 2.44 7.73 ± 1.90 .591‡
Length of hospital stay (days)† 20.94 ± 11.55 18.58 ± 4.05 20.42 ± 10.74 30.82 ± 22.08 .009‡
*Chi-square.
†Presented as mean 6 standard deviations.
‡Analysis of variance (ANOVA).
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discharged until most toxicities have resolved.
The posttransplant-related toxicities stratified by
nutritional status are illustrated in Table 5. There
were no statistically significant differences in the fre-
quency of transplant-related toxicities between pa-
tients who had normal nutritional status and
patients who had mildly compromised nutritional
status. However, there were significant differences
among the nutritional status of patients for duration
of diarrhea, F (2, 123)5 4.80, P5 .010, and length of
hospital stay, F (2, 124)5 4.95, P5 .008. Patients
who had moderately compromised nutritional status
experienced significantly longer duration of diarrhea
(12 days) compared to patients with normal nutri-
tional status (6.5 days, P5 .018) and to patients
with mildly compromised nutritional status (6.6
days, P5 .008). In addition, patients who had mod-
erately compromised nutritional status also experi-
enced significantly longer length of hospital stay
(30.8 days) when compared to patients with normal
nutritional status (18.6 days, P5 .008) and to pa-
tients with mildly compromised nutritional status
(20.4 days, P5 .012).
Patients with moderately compromised nutritional
status were compared against the other 2 nutritional
status groups. There was a trend of higher infection
rate among increasing nutritional compromise
patients from 19% to 73% (MH c25 9.46, P5 .02).
Patients with moderately compromised nutritional
status were 11 times more likely to develop an infec-
tion following APBSCT than patients with normal nu-
tritional status (Wald c25 8.29, odds ratio [OR]
11.24, confidence interval [CI] 2.42-58.82, P5 .004).
We did not find a significant difference in infection
rate between patients with moderately versus mildly
compromised nutritional status (Wald c25 0.05, OR
3.72, CI 0.93-15.0, P5 .823).Stepwise multiple regression analysis corroborated
that length of hospital stay was significantly influenced
by nutritional status, F (2, 126)5 3.39, P5 .037, and
infection, F (1, 126)5 4.20, p5 .042, and that duration
of diarrhea was influenced only by nutritional status, F
(2, 125)5 3.93, P5 .022. Of interest, the Karnofsky
performance status score did not significantly influ-
enced the length of hospital stay or durationof diarrhea.DISCUSSION
Nutritional disorders occur frequently in patients
with cancer because of multiple factors. Chemothera-
peutic agents have multiple side effects on the gastro-
intestinal tract including nausea, vomiting, diarrhea,
and mucositis. In addition, cancer patients frequently
suffer from anorexia, xerostomia, and dysgeusia, which
make oral intake difficult. Complications of cancer
therapies such as infection can induce high metabolic
stress and tissue catabolism. For these reasons, patients
referred for consideration of APBSCT frequently have
compromised nutritional status.
Despite recommendations that routine nutritional
evaluation be carried out before APBSCT transplanta-
tion [6], few clinical trials report the pretransplant
nutritional status. A hurdle to the assessment of pre-
transplant nutritional status is that some nutritional as-
sessment methods require specialized tests and
anthropomorphic measurements, which make nutri-
tional assessments labor intensive. A simple method
of nutritional assessment would be extremely helpful,
especially if this method is quick, inexpensive, and
able to identify patients at high risk of transplant-re-
lated complications. We found that the VA-NSCS,
a simple and inexpensive tool to assess nutritional sta-
tus, was useful in determining the pretransplant nutri-
tional status of patients who underwent APBSCT.
Biol Blood Marrow Transplant 15:1060-1065, 2009 1065Assessment of Nutritional Status Prior to Autologous TransplanationNutritional assessments were completed in 1 visit for
all study patients without the need of obtaining spe-
cialized tests. In addition, this method was able to
identify patients at a higher risk of posttransplant com-
plications. Patients with moderately compromised nu-
tritional status pretransplantation experienced
a higher incidence of infections, longer duration of di-
arrhea, and longer length of hospital stay when com-
pared to patients with normal or mildly
compromised nutritional status.
We also found a significant difference in the Kar-
nofsky performance status score between the moder-
ately compromised nutritional status group and the
normal and mildly compromised nutritional status
groups. This finding is in agreement with other studies
that have found an association between low perfor-
mance status and low lean body mass index in patients
with hematologic malignancies [7]. A state of malnu-
trition prior to APBSCT has been associated with
more severe transplant-related toxicities such as longer
time for neutrophil engraftment, longer length of hos-
pital stay, and higher peritransplant mortality [6,8-10].
Concordance with the results of these studies supports
our findings that the NSCS is useful in the APBSCT
setting.
Although several methodologies have been utilized
for the assessment of nutritional status in patients un-
dergoing transplantation [3,8], it is not clear which
method is more appropriate in this setting [11]. Future
studies should be undertaken to determine the optimal
method for the nutritional assessment of autologous
stem cell transplant candidates, taking into consider-
ation the ability to perform the nutritional evaluation
rapidly and cost effectively.
The results of this study can be generalized to
patients with lymphogenous malignancies undergoing
APBSCT. Other studies should be performed with pa-
tients undergoing allogeneic peripheral blood stem
cell transplantation (PBSCT). It would be important
to replicate this study in other patient population
and compare it to other studies previously described
[8-10]. It will also be important to determine if the
VA-NSCS could be utilized as a screening measure
for intensive nutritional interventions such as total
parenteral nutrition (TPN).
In summary, this study demonstrates that the VA-
NSCS allows for rapid evaluation of the nutritional
status of patients with lymphogenous malignancies be-
fore APBSCT. Patients with moderately compromised
nutritional status had a higher incidence of infections,
longer duration of transplant-related complications,and longer length of hospital stay. Future studies
should focus on the use of VA-NSCS in patients un-
dergoing allogeneic transplantation and in patients
with myelogenous malignancies. Ultimately, early in-
terventions or novel supportive care studies should
be considered for those patients identified with as
higher risks of posttransplant complications.ACKNOWLEDGMENTS
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